830
Participants
Start Date
May 28, 2025
Primary Completion Date
March 14, 2031
Study Completion Date
April 15, 2031
Abiraterone
Assigned prior to enrollment
Enzalutamide
Assigned prior to enrollment
Apalutamide
Assigned prior to enrollment
Darolutamide (BAY 1841788)
Assigned prior to enrollment
Docetaxel
Assigned at enrollment
ADT
Physician's choice. Assigned prior to enrollment
RECRUITING
Ottawa Hospital Research Institute, Ottawa
Collaborators (1)
ECOG-ACRIN Cancer Research Group
NETWORK
NRG Oncology
OTHER
Alliance for Clinical Trials in Oncology
OTHER
SWOG Cancer Research Network
NETWORK
Canadian Cancer Trials Group
NETWORK